Article
ALK in lung cancer: past, present, and future.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2013
Shaw Alice T, Engelman Jeffrey A
Abstract excerpt
In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positive cancers are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. Phase I and II studies of crizotinib in ALK-positive lung cancer demonstrated impressive activity and clinical benefit, leading to rapid US Food and Drug...
Topics
- Anaplastic Lymphoma Kinase
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials as Topic
- Crizotinib
- Drug Resistance, Neoplasm
- Gene Rearrangement
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Pyrazoles
